Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined Vitamins C and K3

Abstract

A combination of Vitamin C and a quinone used as a supplemental treatment for a cancer patient. The combination may be administered before, during and after the patient undergoes a conventional cancer treatment protocol. The combination may be administered orally, intravenously, or intraperitoneally. Oral administration may be in the form of capsules containing a predetermined ratio of Vitamin C to Vitamin K 3 . The supplemental treatment is effective to inhibit metastases of cancer cells and inhibit tumor growth. The ratio of Vitamin C to Vitamin K 3 is in the range of about 50 to 1 to about 250 to 1. A method for evaluating the effectiveness of the supplemental treatment includes monitoring the patient's serum DNase activity throughout the course of treatment.

1 - 63 . (canceled)  
   
   
       64 . A method of inhibiting metastasis of breast cancer cells, colon cancer cells, prostate cancer cells, or liver cancer cells in a host in need thereof, the method comprising the step selected from at least one of: 
 (a) administering orally to said host a first composition consisting essentially of Vitamin C and benzoquinone in an amount synergistically effective to inhibit metastasis of said cancer cells; or,    (b) administering intravenously to said host a second composition consisting essentially of Vitamin C and benzoquinone in amounts synergistically effective to inhibit metastasis of said cancer cells; or    (c) intraperitoneally administering said second composition to said host in amounts synergistically effective to inhibit metastasis of said cancer cells.    
   
   
       65 . The method of  claim 64  wherein said benzoquinone is in a bisulfite form.  
   
   
       66 . The method of  claim 64  wherein the ratio of Vitamin C to benzoquinone in the first and the second compositions is in the range of between about 50:1 and about 250:1  
   
   
       67 . The method of  claim 66  wherein the ratio of Vitamin C to benzoquinone in the first composition is about 100:1.  
   
   
       68 . The method of  claim 64  further comprising prior to said intravenous administration step, a step of preparing said second composition by formulating a solution for intravenous delivery that consists essentially of Vitamin C and benzoquinone.  
   
   
       69 . The method of  claim 68  wherein said formulating comprises the steps of: 
 (a) separately formulating (i) a Vitamin C solution and (ii) a benzoquinone solution; and    (b) mixing (i) and (ii),    thereby formulating said second composition.    
   
   
       70 . The method of  claim 69  wherein the Vitamin C concentration in said Vitamin C solution (i) is about 16.7 mg/ml sodium ascorbate.  
   
   
       71 . The method of  claim 69  wherein the benzoquinone concentration in said benzoquinone solution (ii) is about 10 mg/ml.  
   
   
       72 . The method of  claim 68  wherein said second composition comprises a mixture of about 16.7 mg Vitamin C and about 0.167 mg benzoquinone per ml of diluent.  
   
   
       73 . A method of inhibiting growth of a tumor which tumor is selected from the group consisting of a breast tumor, a colon tumor, a prostate tumor, a lymphoma, a bronchogenic carcinoma, a nonlymphoblastic leukemia, an upper respiratory tract tumor, a brain tumor, a neck tumor, a lung tumor, and a liver tumor, in a subject in need thereof, the method comprising the step selected from at least one of: 
 (a) orally administering to the subject a first composition consisting essentially of Vitamin C and benzoquinone in an amount synergistically effective to inhibit said tumor growth; or,    (b) intravenously administering to the subject, in need thereof, a second composition of Vitamin C and benzoquinone in an amount synergistically effective to inhibit said tumor growth.    
   
   
       74 . A method for treating a form of cancer selected from the group consisting of breast cancer, prostate cancer, colon cancer, liver cancer, lung cancer, lymphoma, bronchogenic carcinoma, nonlymphoblastic leukemia, upper respiratory tract cancer, brain cancer, and neck cancer, in a subject in need of such treatment, the method comprising: 
 (a) orally administering to the subject a first composition consisting essentially of Vitamin C and benzoquinone at a ratio of 100:1 formulated for oral administration;    (b) intravenously administering to said subject a second composition consisting essentially of Vitamin C and benzoquinone at a ratio of 100:1 formulated for intravenous administration;    (c) orally administering to said subject the first composition;    (d) optionally, intravenously administering to said subject the second composition; and;    (e) optionally, orally administering to said subject the first composition.    
   
   
       75 . A method for treating a form of cancer selected from the group consisting of breast cancer, prostate cancer, colon cancer, liver cancer, lung cancer, lymphoma, bronchogenic carcinoma, nonlymphoblastic leukemia, upper respiratory tract cancer, brain cancer, and neck cancer, in a subject in need of such treatment who is also being given conventional cancer treatment, the method comprising: 
 (i) prior to the conventional cancer treatment, orally administering to the subject a first composition consisting essentially of Vitamin C and benzoquinone at a ratio of 100:1 formulated for oral administration; and,    (ii) about one day prior to the conventional cancer treatment, orally administering to the subject the first composition at a second frequency that is higher than said first frequency.    
   
   
       76 . The method of  claim 75 , further comprising the steps of: 
 (iii) on the day of, but prior to, the conventional cancer treatment, orally administering the first composition at said first frequency;    (iv) on the day of, but prior to, the conventional cancer treatment, intravenously administering the second composition; and,    (v) administering the conventional cancer treatment.    
   
   
       77 . The method of  claim 76  further comprising the step of: 
 (vi) on the day following the conventional cancer treatment, orally administering, the first composition.    
   
   
       78 . The method of  claim 76 , wherein the first frequency is once every five hours and the second frequency is once every two hours.  
   
   
       79 . The method of  claim 78 , wherein on the day of, but prior to, the conventional cancer treatment the first composition is orally administered between about 30 minutes and about 180 minutes prior to the conventional cancer treatment, and the second composition is intravenously administered between about 30 minutes and about 180 minutes prior to the conventional cancer treatment.  
   
   
       80 . The method of  claim 74 , wherein the cancer is breast cancer or liver cancer.  
   
   
       81 . The method of  claim 75 , wherein the cancer is breast cancer or liver cancer.  
   
   
       82 . The method of  claim 76 , wherein the cancer is breast cancer or liver cancer.  
   
   
       83 . The method of  claim 77 , wherein the cancer is breast cancer or liver cancer.  
   
   
       84 . The method of  claim 78 , wherein the cancer is breast cancer or liver cancer.  
   
   
       85 . The method of  claim 79 , wherein the cancer is breast cancer or liver cancer.